ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,333.52
-0.91%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.6625
-0.01%
Brent Oil
83.915
0.19%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Cyteir Therapeutics Inc (CYT)

  7. Cyteir Therapeutics Inc (CYT) ニュース

CYT

Cyteir Therapeutics (CYT)

Cyteir Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CYT
日付受信時刻ニュースソース見出しコード企業名
2024/03/0806 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2024/03/0806 : 30Business WireCyteir Announces Timeline for Voluntarily Delisting from NasdaqNASDAQ:CYTCyteir Therapeutics Inc
2024/03/0608 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTCyteir Therapeutics Inc
2024/02/1509 : 36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTCyteir Therapeutics Inc
2024/02/1409 : 14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTCyteir Therapeutics Inc
2023/12/2806 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/12/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTCyteir Therapeutics Inc
2023/12/0806 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/12/0606 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/11/2303 : 47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTCyteir Therapeutics Inc
2023/11/1806 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/11/0706 : 01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTCyteir Therapeutics Inc
2023/10/1305 : 14Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:CYTCyteir Therapeutics Inc
2023/10/1220 : 52Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYTCyteir Therapeutics Inc
2023/10/1220 : 51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/10/1220 : 30Business WireOngoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety ProfileNASDAQ:CYTCyteir Therapeutics Inc
2023/10/0605 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/10/0305 : 44Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:CYTCyteir Therapeutics Inc
2023/08/0805 : 01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTCyteir Therapeutics Inc
2023/07/0106 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTCyteir Therapeutics Inc
2023/06/3023 : 38Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CYTCyteir Therapeutics Inc
2023/06/3023 : 37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYTCyteir Therapeutics Inc
2023/06/3023 : 22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYTCyteir Therapeutics Inc
2023/06/3023 : 22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
2023/06/3021 : 00Business WireCyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionNASDAQ:CYTCyteir Therapeutics Inc
2023/06/2907 : 03Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:CYTCyteir Therapeutics Inc
2023/06/2907 : 02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTCyteir Therapeutics Inc
2023/06/2106 : 54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYTCyteir Therapeutics Inc
2023/06/1505 : 06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYTCyteir Therapeutics Inc
2023/06/0521 : 01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYTCyteir Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYT

最近閲覧した銘柄

BIT
F21458
Vontobel Financial Produ...
COIN
PICAAUSD
PicaArtMoney
GATE
LMUSDT
LeisureMeta
NYSE
DRI
Darden Restaurants
BIT
P1Q6S2
BNP Paribas Issuance
COIN
BENJIBTC
BIT
F30612
Vontobel Financial Produ...
BTHB
ITCKRW
IoT Chain
BIT
P1JO54
BNP Paribas Issuance BV
ASX
SGMKOP
BIT
F39600
Vontobel Financial Produ...
BIT
F38715
Vontobel Financial Produ...
USOTC
GMYTF
GMO Payment Gateway (PK)
BIT
F39636
Vontobel Financial Produ...
BIT
S31903
Societe Generale Effekten
BIT
UR9ZNG
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有